Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Gastrointestinal 1

Conditions

Turcot syndrome 1Rectal Neoplasms 1Neoplasms 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 11Specimen Handling 8X-Rays 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6olaparib 4ulixertinib 3trametinib 3palbociclib 3larotrectinib 3ivosidenib 3erdafitinib 3dabrafenib 3Vemurafenib 3tipifarnib 2tazemetostat 2selpercatinib 2ensartinib 2durvalumab 2Nivolumab 2LY3023414 2Gemcitabine 2Doxorubicin 2Docetaxel 2Cisplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Diffusion Tensor Imaging × Gastrointestinal × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡